Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling Method
News Mar 13, 2018 | Original story from The Scripps Research Institute (TSRI)
Phil Baran, PhD, senior author of the study. Credit: John D. & Catherine T. MacArthur Foundation.
Researchers at The Scripps Research Institute (TSRI) have designed a new molecule-building method that uses sulfones as partners for cross-coupling reactions, or the joining of two distinct chemical entities in a programmed fashion aided by a catalyst. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.
“It’s already clear that this method opens the door to creating new types of compounds and new types of bonds,” says Phil S. Baran, PhD, senior author of the study and Darlene Shiley Professor of Chemistry at TSRI.
This work was inspired by previous cross-coupling chemistry developed in the Baran lab, and catalyzed by discussions with pharmaceutical industry partners who view this as an area of major unmet need. Baran and his colleagues have previously studied decarboxylative cross-coupling reactions, where commonly-found carboxylic acids are transformed into many different molecules using inexpensive metal catalysts and techniques commonly used for amide-bond synthesis. Throughout these studies, Baran and coworkers showed that decarboxylative cross-coupling can have broad applicability and facilitate the synthesis of pharmaceuticals and natural products. These reactions hinge on the transfer of one electron from the metal catalyst to an activated carboxylic acid, which allows for the cross-coupling to occur.
In this work, the authors demonstrate the new desulfonylative cross-coupling reaction by synthesizing over 60 representative molecules, including alkyl-fluorinated compounds inaccessible with earlier generation methodologies developed in the Baran group. Access to such compounds are critical for drug discovery campaigns, since fluorine atoms enhance drug-like molecular properties. Representative molecules described in the Science paper include some reported by Merck and Novartis in published patents.
Baran’s group has already made their sulfone reagents and methods used in this study available to other chemists via Twitter who would like to use the technique. The new method is already having an impact on drug discovery programs at pharmaceutical companies with whom TSRI collaborates.
“I think the job of chemists in academia is to make things simpler. If we can have a small positive influence in making medicinal chemists lives easier, that will be a success for us,” says Baran. “This chemistry is another step in that direction.”
This article has been republished from materials provided by The Scripps Research Institute (TSRI). Note: material may have been edited for length and content. For further information, please contact the cited source.
Merchant, R. R., Edwards, J. T., Qin, T., Kruszyk, M. M., Bi, C., Che, G., . . . Baran, P. S. (2018). Modular radical cross-coupling with sulfones enables access to sp3-rich (fluoro)alkylated scaffolds. Science. doi:10.1126/science.aar7335
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
Tiny Particles Carry Tumor Shrinking Drugs into the BrainNews
MIT researchers have now devised a new drug-delivering nanoparticle that could offer a better way to treat glioblastoma. The particles, which carry two different drugs, are designed so that they can easily cross the blood-brain barrier and bind directly to tumor cells.READ MORE
Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous SclerosisNews
Addressing a critical issue for people with a genetic disorder called tuberous sclerosis complex (TSC), doctors reported that a skin cream containing rapamycin significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with the condition.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018